Core Viewpoint - The company, HeartLink Medical-B (02160.HK), has announced significant growth in its VitaFow® series of transcatheter aortic valves and delivery systems (TAVI), with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The projected implantation volume for 2025 is expected to exceed 850 cases, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFowLiberty® following CE mark approval in European countries and continued market share growth in emerging markets in Asia and Latin America [1] Group 2: Strategic Enhancements - The company's board believes that the recent acquisition of Micro-Invasive Cardiac Management will strengthen local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advance the research and clinical progress of next-generation TAVI products, and enhance its overall competitiveness in the global valve treatment sector [1]
心通医疗-B(02160.HK)：TAVI产品全球覆盖35国家 年植入量预计超850例